Regeneron Reaches New 52-Week High (REGN)

NEW YORK ( TheStreet) -- Regeneron Pharmaceuticals (Nasdaq: REGN) hit a new 52-week high Tuesday as it is currently trading at $121.95, above its previous 52-week high of $121.55 with 140,762 shares traded as of 10:10 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Regeneron has a market cap of $7.18 billion and is part of the health care sector and drugs industry. Shares are up 116.9% year to date as of the close of trading on Monday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

TheStreet Ratings rates Regeneron as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full Regeneron Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.